日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018-2025

2018-2025年中国流行的甲型流感病毒中出现新型PA-D27G突变,导致其对巴洛沙韦的敏感性降低

Sun, Binhuang; Sun, Yulei; Wang, Hongyu; Tang, Xiaolu; Tang, Wanggang; Mi, Yabo; Shen, Zhouying; Xue, Quanlin; Lu, Yinying; Zhao, Xiaoyu; Ai, Jingwen; Lu, Jian; Zhang, Wenhong

Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study

低水平乙型肝炎病毒血症是接受全身治疗的中晚期乙型肝炎相关肝细胞癌患者预后不良的独立预测因素:一项多中心回顾性研究

Lei, Jin; Ma, Huaxing; Chen, Xiong; Lin, Ling; Liang, Zhipeng; Ou, Guangling; Jin, Jiliang; Dai, Hongyuan; Zhang, Ya; Liu, Mei; Li, Haiyang; Lu, Yinying

Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach

肝转移瘤免疫耐受机制的研究进展及“以肝转移为导向的共享机制治疗策略”

Zhang, Qing; Wang, Wenjing; Yu, Hongli; Wang, Fuchuan; Chen, Xiong; Liang, Zhipeng; Lu, Yinying

NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression

NLRP6 缺陷通过 E-Syt1 增强巨噬细胞介导的吞噬作用,从而抑制肝细胞癌的进展。

Li, Shuang; Fu, Yuchen; Jia, Xiaodong; Liu, Zherui; Qian, Zhenwei; Zha, Haoran; Lei, Guanglin; Yu, Lingxiang; Zhang, Xinfeng; Zhang, Ting; Zhang, Tianyi; Han, Jie; Shi, Yuanyuan; Safadi, Rifaat; Lu, Yinying

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan-Sarbecoviruses.

新型三特异性中和抗体,对泛沙贝病毒具有增强的效力和广谱性

Qiao Rui, Liu Yuanchen, Mao Qiyu, Li Jiayan, Lu Yinying, Shi Jialu, Li Chen, Yu Jizhen, Gong Jiami, Wang Xun, Shao Yuchen, Sun Lei, Zhang Wenhong, Yu Hongjie, Chu Hin, Wang Pengfei, Zhao Xiaoyu

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors

溶瘤病毒OVV-01治疗晚期实体瘤的I期、开放标签、多中心、剂量递增安全性和耐受性研究

Hua, Yingqi; Wang, Chongren; Li, Fan; Han, Yanjie; Zuo, Dongqing; Lv, Yu; Sun, Mengxiong; Yuan, Peng; Yuan, Ruirong; Zhang, Fan; Ma, Liang; Wang, Yan; Wu, Hui; Zhou, Guoqing; Lin, Qiang; Wang, Shuhang; Li, Ning; Lu, Yinying

Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma

中国专家共识:靶向治疗联合免疫治疗及局部区域治疗中晚期肝细胞癌

Bi, Xinyu; Lu, Yinying; Chen, Bo; Yang, Zhengqiang; Hong, Zhixian; Wang, Hanping; Sun, Yongkun; Wang, Xiaodong; Yuan, Chunwang; Zeng, Daobing; Huang, Zhen; Zhou, Aiping; Zhang, Wen; Du, Shunda; Zhao, Jianjun; Zhou, Jianguo; Zhai, Yirui; Che, Xu; Zhao, Hong; Zhao, Haitao; Cai, Jianqiang

Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC

原发性耐药与继发性耐药对肝细胞癌患者索拉非尼治疗预后的影响

Lei, Jin; Dai, Hongyuan; Zhang, Ya; Ou, Guangling; Peng Liang, Zhi; Lu, Yinying; Li, Haiyang

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study

乙肝病毒DNA检测不到的肝细胞癌患者接受全身治疗后乙肝病毒再激活及预后:一项多中心回顾性研究

Liang, Zhipeng; Lei, Jin; Li, Haiyang; Dai, Hongyuan; Zhang, Ya; Wang, Fuchuan; Ma, Weihong; Yu, Hongli; Chen, Xiong; Kong, Qinghao; Zhao, Jun; Lu, Yinying

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection

不断发展的SARS-CoV-2疫苗:从现有方案到广谱保护

Qiao, Rui; Li, Jiayan; Gong, Jiami; Shao, Yuchen; Yu, Jizhen; Chen, Yumeng; Lu, Yinying; Yang, Luxuan; Lin, Luanfeng; Hu, Zixin; Wang, Pengfei; Zhao, Xiaoyu; Zhang, Wenhong